ArticleRespirology case reports2025
A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An 80-year-old woman with a lung nodule in the right lower lobe and pleural thickening was diagnosed with lung adenocarcinoma by a surgical lung biopsy. The oncogene panel test showed a positive RET-fusion gene mutation, and selpercatinib was administered as a first-line treatment. She developed severe hyponatremia and was subsequently diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Discontinuing selpercatinib and initiating demethyltetracycline gradually improved SIADH. After confirming that sodium levels had returned to normal, we resumed and continued selpercatinib at a reduced dose without a recurrence of SIADH. This case suggests that selpercatinib could cause SIADH as an adverse event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.